logo
Surgery Resolves Limb Movements in Pediatric Sleep Apnea

Surgery Resolves Limb Movements in Pediatric Sleep Apnea

Medscape5 days ago
TOPLINE:
Periodic limb movements in sleep (PLMS) were found to be common in children with obstructive sleep apnea (OSA), with age and severity of OSA influencing its prevalence. In most cases, adenotonsillectomy effectively resolved PLMS.
METHODOLOGY:
Researchers conducted a retrospective study to evaluate the prevalence of PLMS in children with OSA and assess the effect of adenotonsillectomy on these movements.
They enrolled 1159 children (median age, 5 years; 58.3% boys) with OSA who underwent adenotonsillectomy between January 2022 and July 2023 at a tertiary care children's hospital.
The severity of OSA was categorized using the obstructive apnea-hypopnea index as mild (1-4 events per hour), moderate (5-9 events per hour), or severe (10 or more events per hour).
Elevated periodic limb movement index (PLMI) was measured as PLMS per hour before and after adenotonsillectomy, with an elevated PLMI defined as more than 5 events per hour.
TAKEAWAY:
Children older than 5 years had a higher prevalence of an elevated PLMI than those younger than 5 years (odds ratio, 0.3; P < .001).
The odds of elevated PLMI were 2.3 times higher in children with moderate OSA (P = .007) and 1.9 times higher in those with severe OSA (P = .01) than in those with mild OSA.
The PLMI significantly reduced after adenotonsillectomy (11.9 vs 2.9; P ≤ .001). Among 54 children with an elevated PLMI who underwent follow-up polysomnography, 85% showed resolution after adenotonsillectomy.
Children with residual OSA had a higher PLMI than those without residual OSA (P = .04).
IN PRACTICE:
'The potential clinical implications of our findings are the consideration of AT [adenotonsillectomy] for the initial management of children with OSA and elevated PLMI and counseling caregivers regarding the treatment of elevated PLMI,' the authors of the study wrote.
SOURCE:
This study was led by Amor Niksic, University of Texas Southwestern Medical Center, Dallas. It was published online on June 07, 2025, in The Laryngoscope.
LIMITATIONS:
The retrospective study design limited data collection on sleep characteristics, patient symptoms, the impact of adenotonsillectomy on symptoms, and serum ferritin levels. Additionally, the small number of children who underwent polysomnography before and after adenotonsillectomy may have affected the detection of differences in subgroup analyses.
DISCLOSURES:
The authors reported receiving no specific funding for this work and reported having no conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Samsung's 'Lightning Fast' Galaxy Smartwatch Is 49% Off During Prime Day, and It's 'Amazing for Health Tracking'
Samsung's 'Lightning Fast' Galaxy Smartwatch Is 49% Off During Prime Day, and It's 'Amazing for Health Tracking'

Yahoo

time36 minutes ago

  • Yahoo

Samsung's 'Lightning Fast' Galaxy Smartwatch Is 49% Off During Prime Day, and It's 'Amazing for Health Tracking'

Men's Journal aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission. Samsung's 'Lightning Fast' Galaxy Smartwatch Is 49% Off During Prime Day, and It's 'Amazing for Health Tracking' originally appeared on Men's Journal. Smartwatches have become more than just fitness trackers over the last decade—they're now more like portable smartphones that can truly improve your efficiency. These watches can get a bit pricey, but in the final hours of Amazon Prime Day 2025, you can get this Samsung smartwatch for nearly 50% off. The Samsung Galaxy Watch 7 is typically $300 (for the 40 millimeter Bluetooth options), but Amazon has just marked it down to $152, essentially cutting the price in half. The best discount is on the green 40-millimeter Bluetooth model, but the 44-millimeter and LTE models are also on sale, along with most other colorways. With a modern smartwatch like this, you're getting all of the essential features like a touchscreen AMOLED display, 32 gigabytes of storage, and seamless Android compatibility (this model doesn't work with iPhones, unfortunately). The real kicker with this watch is the Galaxy AI, which works alongside the health tracking features to learn your routine and give you wellness tips, energy scores, and sleep tracking. You can look at all of this data on your (Android) smartphone, and the watch comes with a year-long warranty for some added peace of mind. 'Performance-wise, it's lightning fast. Apps open instantly, navigation is smooth, and the new health features are next-level. I especially love the updated body composition metrics and the improved sleep tracking. The watch gives genuinely useful health insights, not just generic data,' one shopper said. When it comes to the health tracking features, one reviewer wrote, 'the new AI-powered Energy Score feature is a real standout, offering insights into your daily energy expenditure and recovery, helping you optimize your activities for better overall wellness. It's a fantastic feature for anyone focused on maintaining a balanced and healthy lifestyle.' The Samsung Galaxy Watch 7 is available now on Amazon for $150, but Prime Day is coming to a close, so you'd better grab one before it ends. Samsung's 'Lightning Fast' Galaxy Smartwatch Is 49% Off During Prime Day, and It's 'Amazing for Health Tracking' first appeared on Men's Journal on Jul 11, 2025 This story was originally reported by Men's Journal on Jul 11, 2025, where it first appeared.

What to know about the pneumonic plague after Arizona patient's death
What to know about the pneumonic plague after Arizona patient's death

Washington Post

timean hour ago

  • Washington Post

What to know about the pneumonic plague after Arizona patient's death

A person has died of the pneumonic plague at the Flagstaff Medical Center in Arizona, according to Northern Arizona Healthcare, the organization that runs the hospital. The patient arrived at the emergency department and died the same day, a spokesperson for the organization said in an emailed statement. Coconino County, which includes Flagstaff, said it received test results confirming the patient's condition on Friday. The patient was a county resident, it said.

What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill
What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill

Yahoo

timean hour ago

  • Yahoo

What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill

Medtronic is approaching five decades of dividend growth. AbbVie rose to the challenge when its Humira patent expired, cementing its sterling reputation. Johnson & Johnson is a model of consistency and excellence among dividend stocks. 10 stocks we like better than Medtronic › Dividend investing, like most things in life, can be rewarding if done correctly or a headache if you make crucial mistakes. The key to dividend investing is to pick the right types of dividend stocks. But what does a good dividend stock look like? It will be hard to go wrong if you invest in companies with these three traits: Operating in large industries with room for growth. Consistently profitable, with strong balance sheets. Already paying a dividend, with a track record of increasing it. The healthcare industry is a behemoth, with annual expenditures totaling $4.9 trillion in the United States alone. It's a great place to look for dividend stocks you would want to own. Here are three healthcare stocks that fit the bill, making them excellent additions to any dividend investor's long-term portfolio. Leading healthcare companies have built sterling reputations through decades of excellence. Medtronic (NYSE: MDT) certainly fits that bill. The healthcare technology company develops products for treating a wide range of conditions across its four focus areas: Cardiovascular, diabetes, medical-surgical, and neuroscience. It's an engine for constant innovation, with over 190 active clinical trials and 43,000 active patent matters. In total, Medtronic has treated over 78 million patients and operates globally. Medtronic has a storied history of dividend growth, including 47 consecutive annual dividend increases. Upon its 50th consecutive increase, it will become a Dividend King, part of a small group of elite companies that have maintained uninterrupted dividend growth for five decades or more. Additionally, Medtronic yields 3.2% at its current share price, providing a solid starting yield to complement its consistent growth. Medtronic is not resting on its success and is making some bold moves to keep driving growth. It's spinning off its diabetes business to focus on higher-margin areas and is developing its first robotic surgery system. Overall, analysts estimate that Medtronic will grow earnings by an average of 6% to 7% annually over the next three to five years, positioning the stock to become a Dividend King. Pharmaceutical giant AbbVie (NYSE: ABBV) is a leader in one of the most lucrative segments (pharmaceuticals) in the healthcare industry. Its success with Humira, a top-selling drug for years, built AbbVie into an industry giant. The company has pivoted masterfully since the expiration of Humira's patent in 2023. Emerging star drugs Rinvoq and Skyrizi appear to be home runs, and AbbVie's $63 billion acquisition of Allergan, the maker of Botox, helped bolster its product portfolio and pipeline. AbbVie has only been around since its 2013 spin-off from Abbott Laboratories. However, the stock still gets credit for those pre-spin-off decades of dividend growth, making AbbVie a Dividend King with 53 consecutive increases. Shareholders have enjoyed a potent combination of yield and growth. The stock yields 3.5%, and AbbVie has raised its dividend by an average of 7.7% over the past five years. Now, AbbVie's future looks as bright as ever. Analysts expect AbbVie to generate just shy of $60 billion in revenue this year, a record high, and for earnings to grow by an average of 13% annually over the long term. Sustained success in the pharmaceutical world depends on strong product development, and AbbVie's ability to quickly retool for growth post-Humira speaks volumes about the company's world-class quality and execution. In a crowded industry, Johnson & Johnson (NYSE: JNJ) may have the most widely recognized name of any healthcare company. Once known for its popular consumer products, such as Tylenol and Band-Aid, Johnson & Johnson spun off its consumer segment as Kenvue in 2023, allowing the company to focus on growth in pharmaceuticals and medical devices. Johnson & Johnson is a legendary stock for multiple reasons. It's one of just two publicly traded companies with an AAA credit rating. That's even higher than the U.S. government, which can essentially print money to pay its bills. Additionally, the company has paid and raised its dividend for a whopping 62 consecutive years. Analysts estimate that the company will grow earnings by an average of just over 6% annually over the next three to five years. Given the fortress-like balance sheet and a dividend payout ratio of only half the company's 2025 estimated earnings, the steady growth is sufficient to fund dividend increases for years to come. Plus, investors start with a generous 3.3% yield. Johnson & Johnson's clockwork-like consistency makes it an ideal dividend stock to buy and hold, and then reinvest the dividends, maximizing the stock's total returns by enhancing the compounding effect over time. Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $694,758!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $998,376!* Now, it's worth noting Stock Advisor's total average return is 1,058% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, and Kenvue. The Motley Fool recommends Johnson & Johnson and Medtronic and recommends the following options: long January 2026 $13 calls on Kenvue, long January 2026 $75 calls on Medtronic, and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store